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There are various sources of MSCs. They can be 
obtained from both infant and adult tissues. Infant 
tissues mainly include umbilical cord (UC) tissues, cord 
blood cells and developing tooth buds of the mandibular 
third molar. MSCs can be derived from adult tissues as 
well, most commonly from the bone marrow, others from 
the umbilical cord, placenta, adipose tissue, muscles, 
peripheral blood, synovial fluid and articular cartilages. 
Infant tissues MSCs contain more multipotent primitive 
MSCs compared with adult tissues. They are able to 
differentiate into cells of all three germ layers, whilst the 
adult MSCs have restricted differentiation potential.
Detection of MSCs is mainly based on Mesenchymal 
and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy minimal criteria (1). MSCs 
should have a long thin body with a large nucleus; have 
a fibroblast-like morphology; express on their surface 
CD73, CD90 and CD105; lack expression of CD11b, CD14, 
CD19, CD34, CD 45 or HLA-DR molecules; and possess 
differentiation capability. However, no single isolation 
method is regarded as the standard practice so the criteria 
allow only a retrospective classification of cultured cells 
as containing MSCs.
Functions of MSCs in vivo in normal individuals are 
not fully understood. There are multiple hypotheses for 
underlying functions of MSCs. MSCs can differentiate 
into osteoblasts, which are essential components of the 
bone marrow (BM) environment. Thus, MSCs can have 
regulatory role of haematopoietic development in bone 
marrow.
1.1  Mechanisms of MSCT in autoimmune 
diseases
There are various mechanisms of MSCs in regulation 
of autoimmune disease activity. First, MSCs can work 
as immunomodulators that can balance Th1/Th2 cells 
numbers and expressions. Second, MSCs promotes 
the production of Tregs, which suppress the activity of 
autoreactive T cells. Third, MSCs can differentiate into 
DOI 10.1515/hkbrd-2016-0002
Received June 01, 2016; accepted June 07, 2016  
Abstract: Mesenchymal stem cell therapy (MSCT) is an 
innovative treatment for rheumatic diseases. Underlying 
mechanism of how MSCT works in rheumatic diseases 
are still uncertain and with various hypotheses. Animal 
studies in MSCT show conflicting results mainly attribu-
ted by the differences in administration methods of MSCT, 
types of MSC use and randomization procedures. Human 
studies of MSCT are so far small scale but with satisfac-
tory results in patients with systemic lupus erythemato-
sus (SLE). Human studies of MSCT, however, showed less 
rewarding results in patients with rheumatoid arthritis 
(RA) and systemic sclerosis (SSc). Larger scale studies are 
needed to confirm the efficiency of MSCT as well as the 
safety profile in human use.
Keywords: Mesenchymal Stem cells, systemic lupus 
erythromatosis, rheumatoid arthritis, systemic sclerosis
1  Introduction
Mesenchymal stem cell (MSC) is a multipotential non-
haematopoietic progenitor cell that is able to differentiate into 
various cell lineages. MSC can differentiate into osteoblasts, 
chondrocytes, myocytes, adipose tissues, endothelial cells, 
neuron-like cells, cardiomyocytes and hepatocytes. MSCs 
lack expression of co-stimulatory molecules, are capable of 
escaping from alloantigen recognition and, hence, have low 
immunogenicity. This is why MSCs are candidate cells to 
prevent rejection in transplant therapy and can be a potential 
treatment option for rheumatic diseases.
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different cell types, for example, endothelial cells that 
may help reconstruct the structure of nephrons and 
improve renal function. At present, no data can confirm or 
refute these hypotheses.
2  MSCT in SLE
2.1  Mechanisms
There are multiple mechanisms of MSCT in the treatment 
of systemic lupus erythematosus (SLE). MSCs can 
increase the levels of IL-10, which is important for the 
Treg cell activation and function in the peripheral blood. 
UC-derived MSCs depress IL-4 levels, which can suppress 
antibody production. Patients with SLE usually suffer 
from osteoblastic niche deficiency in the bone marrow, in 
both patients and mouse models, compared with normal 
healthy subjects. MSCs can differentiate into osteoblasts 
that may regulate inflammatory reaction.
2.2  Timeline of MSCT development in SLE
Sun et al. (2) and Nie et al. (3) suggested that there were 
functional abnormalities in bone-marrow-derived MSCs 
in patients with SLE, compared with mice and age and 
sex-matched healthy individuals, respectively. As patients 
with SLE have defective bone-marrow-derived MSCs, 
allogenic rather than autologous MSC transplantation 
may be an effective treatment for SLE.
In order to show that autologous MSCT is useful in 
SLE, various animal studies had been performed, but they 
showed conflicting results. Schena et al. (4) suggested that 
mice with SLE, after intravenous infusion of bone-marrow-
derived MSC, had no effect on autoantibody production, 
proteinuria or mortality, despite improvement in the 
histological features of the kidney. Youd et al. (5) concluded 
that , the use of allogenic bone-marrow-derived MSCs in 
mice with SLE worsened the disease activity, increased the 
level of autoantibody and proteinuria. In contrast, in Gu 
et al. (6) and Zhou et al. (7), after the use of UC-derived 
MSC and bone-marrow-derived MSC, respectively, SLE 
mouse models had clinical improvements, together with 
reduction in anti-double-stranded DNA (anti-ds DNA), 
proteinuria and creatinine levels.
On the other hand, human application of MSCT 
in patients with SLE, compared with animal studies, 
showed more rewarding results. In an initial small-scale 
human study in Carrion et al. (8), autologous bone-
marrow-derived MSCs were administered intravenously 
in two patients with SLE. It showed no clinical 
improvement in the disease activity, and renal flare was 
even diagnosed in one patient 4 months after MSCT. 
However, as the follow-up period was 14 months only, 
conclusion of inefficacy could not be drawn. Subsequent 
studies showed more promising results in MSCT. Sun et 
al. (9) demonstrated the success of MSCT in four patients 
with refractory SLE. Two of them had completely taken 
off cyclophosphamide after 6 months of MSCT use. All 
patients were able to tail down the daily steroid dose 
to less than 10 mg of prednisolone. Improvements in 
secondary outcomes such as significant reduction on 
the systemic lupus erythematosus disease activity index 
(SLEDAI) and proteinuria were observed in all patients 
at 12 months after MSCT. Liang et al. (10) and Sun et al. 
(11) illustrated the improvement in the disease activity in 
patients with SLE. In Liang et al., 16 patients suffered from 
SLE with life-threatening organ involvement and who 
were refractory to treatment were enrolled. After MSCT, 
there was significant reduction in anti-ds DNA and anti-
nuclear antibody (ANA) titers in 1 month and 3 months 
post-transplant. There was also significant improvement 
of renal function and urine protein excretion. Patients 
even had improvements in non-lupus-nephritis-related 
manifestations, for example, constitutional symptoms 
of fatigue, weight loss and low-grade fever, cutaneous 
lesions, arthralgia and refractory pancytopenia.
Subsequent human studies of MSCT in patients with 
refractory SLE guide our methods of application of MSCT 
in order to have an optimal response. In Wang et al. (12), 
58 patients with refractory SLE were randomized into 
two groups, with 30 patients receiving single MSCT and 
28 patients receiving double MSCT. In patients receiving 
double MSCT, the second MSCT was received a week after 
the first infusion of MSCs. Surprisingly, the rate of complete 
remission was higher in the single transplantation group 
compared with multiple transplantation group (p = 0.006). 
On the other hand, there was no significant difference in 
the rate of disease relapse between single transplantation 
group and double transplantation group (p = 0.784). 
This study highlighted that single MSCT would be the 
mode of future application in patients with SLE. In Wang 
et al. (13) and Wang et al. (14), larger number of subjects 
in multiple centres were recruited for intravenous bone 
marrow or umbilical cord MSCT. Both studies showed 
positive results with better survival rates and clinical 
responses. One important point to note in Wang et al. 
was that patients were randomized into two groups, one 
with and one without cyclophosphamide pre-treatment. 
There was no significant difference in complete clinical 
remission, SLEDAI score, proteinuria and serum albumin 
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level between the two groups. Hence, cyclophosphamide 
pre-treatment may not be necessary before MSCT.
Contrary to MSCT in patients with SLE, haematopoietic 
stem cell (HSC) transplantation was only once studied in 
patients with SLE. It not only caused significant clinical 
improvement but also with significant mortality and 
morbidity, for example, mucositis, transplantation-
related infection and lung injury.
3  MSCT in RA
3.1  Mechanisms
In patients with rheumatoid arthritis (RA), there is influx 
of fibroblast-like synoviocytes (FLS) into the joints. FLS are 
considered to be the ‘diseased’ MSCs. They are involved 
in pannus formation, synovial inflammation and tissue 
damage. FLS are able to produce inflammatory cytokines 
that cause further joint destruction and suppress MSC 
repair function within the joint. Hence, they are considered 
to be pathogenic cells that contribute to chronicity and 
progression of RA.
MSCs are able to produce anti-inflammatory cytokines 
to reduce deleterious Th1/Th17 response and inhibit B 
cells function and differentiation. They can also reduce 
the expression of human leukocyte antigen DR (HLA-
DR) and CD80 and CD 86 co-stimulatory molecules on 
antigen-presenting cells, which can help reduce synovial 
inflammation.
Apart from anti-inflammatory effect, MSCs can 
differentiate into different cell types, for example, 
osteoblasts for bone regeneration. Also, MSCs can produce 
osteoprotegerin, which can block receptor activator of 
nuclear factor-kappa B ligand (RANKL)-receptor activator 
of factor-kappa(RANK) interaction and, hence, inhibit 
osteoclastogenesis.
Current conventional disease modifying anti-
rheumatic drugs (DMARDs) and biological DMARDs 
are able to suppress joint inflammation. In contrast 
to DMARDs, effective MSCT in patients with RA may 
help cartilage and joint regeneration in addition to 
inflammation suppression effect, which sounds more 
attractive.
3.2  Timeline of MSCT development in RA
Conflicting results were shown in MSCT in animal models. 
Some studies such as Augello et al. (15) and Gonzalez et al. 
(16) suggested that MSCT was able to prevent the incidence 
and reduce the severity of arthritis in mice models. Both 
studies discussed that MSCs were not localized in the 
joints only and that intra-articular injection of MSCs was 
less effective than intraperitoneal route. Both studies 
had drawn a conclusion that clinical improvement 
might not be confined to the localized effect of MSCs in 
joints. In contrast, Djouad et al. (17), Chen et al. (18) and 
Schurgers et al. (19) were negative studies of MSCT in RA 
mice models. In Schurgers et al., both intravenous and 
intraperitoneal route of MSC were administered but lack 
of response in CIA mice models was noted. One of the 
potential reasons for the conflicting results is that there 
were discrepancies in the sources of MSCs, tissues of 
origin, routes of administration and treatment regimens 
in various studies. Consequently, direct comparison of 
studies in mice models was not feasible.
In human studies, unfortunately, they also showed 
conflicting results in patients with RA. In Liang et al. (20), 
four patients with refractory RA received intravenous 
infusion of allogenic bone-marrow-derived or UC-derived 
MSCs. Refractory RA is defined as established RA with 
resistance to conventional DMARDs and at least one anti-
tumour necrosis factor α (anti-TNFα). MSCT could only 
result in a partial and transient clinical improvement. In 
Wang et al. (21), a larger sample size was obtained, with 
136 patients in treatment of intravenous injection of MSC 
with DMARDs and 36 patients in treatment of DMARDs 
without MSCs. It showed significant improvement in 
MSCs group in terms of clinical response and increase 
in the percentage of regulatory T cells in peripheral 
blood. Further studies will be needed for any conclusive 
evidence for the application of MSCT in patients with RA.
Another potential reason for conflicting results 
in MSCT studies in RA is that the effective mode of 
administration of MSCs is still unknown. A comparative 
study of MSCs showed that intra-articular MSCs were 
superior in cartilage formation compared with other 
modes of administration (22). In previous studies, intra-
articular administration of MSCs had a low efficacy in 
patients with RA (23). A new delivery method of MSCs 
using nanofibre poly-lactic-co-glycolic acid (PLGA) 
was proposed (24). PLGA sheet was applied topically 
over joints. The pros of using PLGA were controlled 
biodegradability, low immunogenicity and that they 
were useful as a scaffold for the regeneration of bone 
defect and cell regeneration. Yet, the application of PLGA 
is still rudimentary and needs further animal and human 
studies. Other future perspectives of MSCT in patients 
with RA include identifying the subset of patients with 
RA responsive to MSCT and combination of MSCT and 
anti-TNFα therapy for theoretical synergistic effect.
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3.3  MSCT in Systemic Sclerosis (SSc)
The main mechanism of MSCT in systemic sclerosis (SSc) 
is the inhibition of proliferation of T lymphocytes and B 
lymphocytes. BM-derived MSCs from patients with SSc 
appeared similar to those healthy individuals in their 
phenotype and capacity to differentiate into adipogenic 
and osteogenic lineages and similar immunosuppressive 
properties. However, patients with SSc have a diminished 
capacity to differentiate into endothelial progenitor cells 
and to contribute to vasculogenesis. In other words, 
theoretically, autologous MSCT may be useful in patients 
with SSc.
However, the use of MSCT in SSc is still preliminary. 
One case study suggested UC-derived MSCT in patients 
with SSc who had leg ulcers refractory to steroid, 
cyclophosphamide and plasma exchange treatment 
showed improvement in modified Rodnan Skin Score and 
health assessment questionnaire disability index score 
(25). Another case series, which included five patients 
treated with intravenous-bone-marrow-derived MSC 
showed the improvement in mRSS and ulcerations but no 
significant improvement in lung function, lung fibrosis 
and cardiac function (26).
In contrast to MSCT in patients with SSc, use of 
hematopoietic stem cells transplantation (HSCT) has 
been more rewarding. An international multi-centre, 
open-label phase III study, named Autologous Stem Cell 
Transplantation International Scleroderma (ASTIS) trial, 
enrolled 156 patients and it suggested that HSCT group 
patients had a significantly better long-term survival rate 
than the intravenous cyclophosphamide group (27).
4  Conclusion
MSCT in rheumatic diseases is getting more and more 
attention. Source of MSC varies, mainly bone marrow 
and umbilical cord. The route of administration is 
mainly intravenous, but intraperitoneal and topical are 
occasionally used. MSCT seems to be more rewarding in 
patients with refractory SLE, has mixed results in patients 
with RA and is not quite effective in patients with SSc. 
More multicenter, randomized controlled human studies 
should be performed in order to make a conclusion to the 
efficacy of MSCT in rheumatic diseases.
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